Services > Ophthalmology > Research
DEPARTMENT OF OPHTHALMOLOGY
RESEARCH DIVISION

 

The Loma Linda University Healthcare, Department of Ophthalmology would like to introduce you to our Research Division. Loma Linda has been actively involved in many clinical trials involving diseases of the eye. The following is a brief list and description of the type of research projects that we are conducting. If you are interested in having your patients participate in these studies, please contact our Research Department at (909) 558-2170 or (909) 558-2168 for more information.
 

DRCR-S: Prompt Panretinal Photocoagulation versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy


 

 Principal Investigator: Joseph T. Fan, MD

Sub-Investigators: Michael E. Rauser, MD & Mukesh B. Suthar, MD

 

 

Study Objective: This protocol is to determine if vision at 2 years in eyes with Proliferative Diabetic Retinopathy that receive Ranibizumab injections with deferred PRP (laser) are worse than those in eyes that receive standard laser only.
 
Patients might be eligible to participate in this study if they:
  • Age >=18 years
  • Diagnosed and is currently being treated for type 1 or type 2 diabetes
  • Best corrected vision E-EDTRS is 20/320 or better.
  • Have presence of PDR in which the investigator feels that laser can be deferred for at least 4 weeks in the setting of intravitreal ranibizumab.
  • Has no history of prior Panretinal Photocoagulation (prior PRP is defined as 100 burns outside of the posterior pole)
 
Our doctors will confirm through a retinal exam if the patient is eligible. The cataract surgery will be performed by the patients own cataract surgeon in their usual fashion (there will be no restrictions on pre-, peri, or post-op treatments. 

 

Implantable Miniature Telescope for End-Stage AMD

A Prospective, Multicenter Post-Approval Study (PAS) Of Visioncare’s Implantable Miniature Telescope (By Dr. Isaac Lipshitz) In Patients With Bilateral Severe To Profound Central Vision Impairment Associated With End-Stage Age-Related Macular Degeneration

 

 Principal Investigator: Michael E. Rauser, MD

 

 

Study Objective: The objective of the study is to assess the safety of the intraocular telescope as measured by the cumulative incidence of patients within 5 years after implantation experience persistent vision-impairing corneal edema
Patients may be eligible to participate in this study if they meet the following criteria:
  • Have retinal findings of geographic atrophy or disciform scar with foveal involvement
  • Have evidence of visually significant cataract (> Grade 2)
  • Agree to undergo pre-surgery training and assessment with low vision specialists in the use of an external telescope sufficient for patient assessment and for the patient to make an informed decision
  • Achieve at least a 5-letter improvement on the ETDRS chart with an external telescope
  • Have adequate peripheral vision in the eye not scheduled for surgery
  • Agree to participate in a postoperative visual training with a low vision specialist
  • No diagnosis of Stargardt’s macular dystrophy
  • Have an central anterior chamber depth > 3.0mm
 

Home Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device


 

 Principal Investigator: Michael E. Rauser, MD

 

 

The objective of this study is to determine if home monitoring using the comprehensive visual field and telemedicine solution based on the ForeseeHome device in participants at high risk of progression to neovascular AMD improves detection of progression to choroidal neovascularization when compared to standard care.

Patients might be eligible to participate in this study if they:

  • Male or female - 55 years of age or older• Male or female - 55 years of age or older
  • Must have bilateral large drusen (≥ 125 microns) or large drusen in the posterior pole in one eye and advanced AMD in the fellow eye. Participant must have intermediate AMD in at least one eye
  • Pt does not have advanced AMD (neovascular AMD or central geographic atrophy) in at least 1 eye
  • Eye(s) with intermediate AMD must have best corrected visual acuity 20/60 or better (at least 54 letters)
 

For more information on any of the above studies please contact one of our Research Division Coordinators:

 

  • Brandi Perez - (909) 558-2168
  • Kara Halsey - (909) 558-2170
  • Gisela Santiago - (909) 558-2112
Loma Linda University Healthcare
Department of Ophthalmology 
Research Division
11370 Anderson Street, Suite 1800
Loma Linda, CA 92354

back to home